Compare Recursion Pharmaceuticals Inc (RXRX) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $434.7 (market cap $2.03T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 1091.4× Recursion Pharmaceuticals Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TSM | |
|---|---|---|
Market Cap | $1.86B | $2.03T |
Sector | Health | Technology |
52-Week High | $6.79 | $477.57 |
52-Week Low | $2.84 | $258.91 |
Enterprise Value | $1.38B | $1.95T |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
TSM trades at $439.00, up 2.35% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is near its pivot point of $439, with support at $434 and resistance at $444. Revenue grew to $3.81T in 2025, with a net income margin of 44.56%, while analysts project a consensus price target of $541.29. Recent news highlights TSMC's leadership in AI-driven semiconductor demand and advancements in chipmaking technology.
The outlook for TSM remains positive, driven by robust AI demand and operational execution, though risks include geopolitical tensions and high capital expenditures. With 72% of analysts rating it a Buy and no Sell ratings, the stock offers growth potential, but investors should monitor competitive pressures and global semiconductor cycle volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
